Schering Corporation

Shmuel Zbaida

Kevin B Alton

Anima Ghosal

Swapan K Chowdhury

James E Patrick

Wenqing Feng

Robert M Iannucci

Andrew William Stamford

Ronald J Doll

Craig D Boyle

Harry R Davis

Keith P Minor

Tze-Ming Chan

Wei Tong

Mark A Wirth

The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for preparing the same. Further disclosed are methods of treating a physiological disorder, symptom or disease in a patient, comprising administering to the patient an effective amount of the above compound, wherein the physiological disorder, symptom or disease is a urogenital, cardiovascular, cerebrovascular or peripheral vascular disorder, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, a respiratory tract disorder such as an allergic condition associated with atopy, pulmonary hypertension, an ischemic heart disorder, impaired glucose tolerance, diabetes and its related complication, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, a glomerular disorder, renal insufficiency, nephritis, a tubular interstitial disorder, an autoimmune disorder, glaucoma, intestinal motility, cachexia or cancer.

Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

The present invention relates to metabolites of tricyclic amides, and structurally related compounds, represented by the structural formula (I):  Also disclosed are methods of treatment of proliferative diseases and methods for inhibiting the abnormal growth of cells, and for inhibiting farnesyl protein transferase using the novel compounds.

Metabolites of tricyclic amides useful for inhibition of G-protein function and methods of treatment of proliferative diseases

Hypocholesterolemic substituted 2-azetidinone compounds of the formula:are disclosed, as well as a methods of lowering cholesterol by administering said compounds, pharmaceutical compositions containing them, and the combination of a substituted 2-azetidinone cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for the treatment and prevention of atherosclerosis.

Substituted 2-azetidinones useful as hypocholesterolemic agents

Growing community of inventors

East Brunswick, NJ, United States of America

Shmuel Zbaida